| Previous Close | 9.37 |
| Open | 9.37 |
| Bid | 9.13 x 800 |
| Ask | 11.40 x 900 |
| Day's Range | 9.12 - 9.52 |
| 52 Week Range | 3.60 - 25.77 |
| Volume | 60,303 |
| Avg. Volume | 239,756 |
| Market Cap | 664.914M |
| Beta (3Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years. Viaskin Peanut is the Company’s lead product candidate based on epicutaneous immunotherapy (EPIT®).
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The interim financial report is available on the Investor Relations section of the Company’s website, www.dbv-technologies.com/investor-relations/. First half 2019 financial statements were subject to a limited review by the Company’s external auditors.
AMF REGULATED INFORMATIONMontrouge, France, July 18, 2019 Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report DBV Technologies.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Pharis Mohideen, M.D., as its Chief Medical Officer (CMO), effective July 22, 2019. Dr. Mohideen will serve as a member of the Executive Committee and report to Daniel Tassé, Chief Executive Officer of DBV Technologies.
Montrouge, France, June 3, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a.
Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of.
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting, which was chaired by Michel de Rosen, Chairman of DBV Technologies. At the General Meeting, the Company’s shareholders approved all resolutions submitted by the Board of Directors.
Montrouge, France, May 14, 2019 DBV Technologies Announces Departure of Deputy CEO David Schilansky DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock.
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today that it will hold its Ordinary and Extraordinary General Meeting on May 24, 2019 at 8:30 a.m. CEST at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The documents for the General Meeting will also be made available to shareholders as of the date of the issuance of the convening notice.
Montrouge, France, April 30, 2019DBV Technologies Reports March 31, 2019 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an underwritten global offering of an aggregate of 6,000,000 ordinary shares reserved to specified categories of investors in (i) an offering of 2,447,500 ordinary shares in the form of 4,895,000 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe, at an offering price of $6.75 per ADS (on the basis of an exchange rate of $1.1233 = €1.00), and (ii) a private placement of 3,552,500 ordinary shares in Europe (including France), at an offering price of €12.02 per ordinary share. The number of ordinary shares (including in the form of ADSs) sold in the global offering reflect the exercise in full of the underwriters’ option to purchase additional ordinary shares (including in the form of ADSs). The total gross proceeds from the global offering, including from the exercise of the underwriters’ option to purchase additional ordinary shares (including in the form of ADSs), were approximately $81.0 million (€72.1 million), before deducting commissions and estimated offering expenses.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its previously announced global offering reserved to specified categories of investors have exercised in full their option to purchase 782,608 additional ordinary shares in the form of 1,565,216 American Depositary Shares (“ADSs”), at an offering price of $6.75 per ADS, before deducting commissions and estimated offering expenses (the “Option”). Each ADS represents the right to receive one-half of one ordinary share, and the offering price of $6.75 per ADS corresponds to a price of €12.02 per ordinary share (on the basis of an exchange rate of $1.1233 = €1.00). The closing of the Option is expected to occur on April 8, 2019, subject to customary closing conditions, concurrently with the balance of the global offering.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the pricing of a global offering of an aggregate of 5,217,392 ordinary shares reserved to specified categories of investors in (i) an offering of 1,664,892 ordinary shares in the form of 3,329,784 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe at a public offering price of $6.75 per ADS (on the basis of an exchange rate of $1.1233 = €1.00) and (ii) a private placement of 3,552,500 ordinary shares in Europe (including France), at a public offering price of €12.02 per ordinary share. The price at which the ordinary shares (including in the form of ADSs) will be sold in the global offering is equal to the average of the trading prices of the Company’s ordinary shares on Euronext Paris over five (5) consecutive trading days chosen from among the thirty (30) trading days prior to pricing of the global offering less a discount of 8.6%.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its intention to issue and sell, subject to market conditions, in a global offering of new ordinary shares, which may be in the form of American Depositary Shares (ADSs), up to 5,217,392 new ordinary shares, the subscription of which is reserved to specified categories of investors. The global offering will be comprised of an offering of ADSs in the United States, Canada and certain other countries outside of Europe and a private placement of ordinary shares in Europe (including France).
Montrouge, France, April 1, 2019 DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN:.
NEW YORK , March 28, 2019 /PRNewswire/ -- Atlas Financial Holdings, Inc. (AFH) Lifshitz & Miller announces investigation into possible securities laws violations in connection with "actuarial work ...
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
NEW YORK, March 18, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against DBV Technologies.
NEW YORK, March 18, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
LOS ANGELES, CA / ACCESSWIRE / March 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against DBV Technologies S.A. (''DBV ...